quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 14, 2026

Citi targets 10%-11% 2026 RoTCE while keeping efficiency ratio around 60% and U.S. card NCL rate at 4%-4.5%

View original at seekingalpha.com
“Jane Fraser said Citi had "an exceptionally strong start to 2026," reporting "net income of $5.8 billion for the first quarter with an EPS of $3.06 and an RoTCE of 13.1%," ... Gonzalo Luchetti (Chief Financial Officer) said, "This quarter, we reported net income of $5.8 billion, EPS of $3.06 and an RoTCE of 13.1%, on $24.6 billion of revenues,"”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Banamex deconsolidation would bring about $8.5 billion CTA adjustment but in aggregate it's capital neutral

    60% confidence
  • Overall revenues were up sharply at 14% with very healthy positive operating leverage

    60% confidence
  • Citi does not anticipate any additional stake sales in Banamex in 2026 ahead of deconsolidation in early 2027, with IPO most likely happening after that when market conditions are favorable

    60% confidence
  • The impact of Middle East conflict is hitting Asia and Europe harder, and inflation is now a greater risk to growth likely causing central banks to lean towards more restrictive monetary policies

    60% confidence
  • Citi expects a moderate net benefit from Basel/G-SIB rules

    60% confidence
  • Markets crossed $7 billion in revenues for the first time in a decade, with Equities up nearly 40% surpassing $2 billion and FICC up 13%

    60% confidence
  • One good-rate first quarter does not make a full year, citing uncertainty and continued investment as reasons Q1 RoTCE may decline to 10%-11% range

    60% confidence
  • M&A pipeline continues to be quite strong, but prolonged conflict may start introducing risk of deferrals

    60% confidence
  • Citi remains well on track to deliver 10% to 11% RoTCE for the full year 2026

    60% confidence
  • 90% of transformation programs are now at or near target state

    60% confidence
  • Overall expectations are unchanged with NII ex-Markets up approximately 5% to 6%, efficiency ratio around 60%, and U.S. card NCL rate between 4% and 4.5%

    60% confidence
  • Citi had an exceptionally strong start to 2026 with net income of $5.8 billion, EPS of $3.06, and RoTCE of 13.1%

    60% confidence
  • Expenses of $14.3 billion were up 7%, but excluding nearly $500 million of severance, the increase was only 4%

    60% confidence
  • Banking fees were up 12% with a record first quarter in M&A and ECM up over 60%

    60% confidence
  • Services growth is driven by deepening with existing clients, new client acquisition and new product innovations, and Citi is leading in tokenization in digital assets

    60% confidence
  • Private credit exposure is $22 billion with 98% investment-grade, describing it as not a significant exposure

    60% confidence
  • Services is Citi's crown jewel with new mandates up 40%, revenues up 17%, deposits up 16%, and assets under custody up over 20%

    60% confidence
  • Citi is close to completing the $20 billion share buyback plan and ended quarter with CET1 ratio of 12.7%, 110 basis points above regulatory requirement

    60% confidence
  • Citi ended quarter with nearly $22 billion in total reserves and reserve-to-funded loans ratio of 2.6%, incorporating 8-quarter weighted average unemployment rate of 5.4% with downside scenario nearly 7%

    60% confidence
  • The latest NPR is an improvement but not yet where it should be, and Citi will be active in advocating for necessary changes

    60% confidence
  • Citi will provide more detail on share repurchase expectations at Investor Day in May

    60% confidence
  • Reserves were adjusted with further skew to downside scenario reflecting increased uncertainty in macroeconomic outlook

    60% confidence
  • The last 10% of transformation is primarily related to data used in regulatory reporting, and regulators control the timeline for closure

    60% confidence
  • Citi is only interested in and focused on organic growth, period, end of story, with no interest in retail banking acquisitions

    60% confidence
  • Citi is not interested in anything other than organic growth

    60% confidence

Data points we hold from this source

Citigroup Inc. · cet1 ratio12.7 percent
Citigroup Inc. · severance costs500 USD
Citigroup Inc. · expense growth7 percent
Citigroup Inc. · share buybacks6.3 USD
Citigroup Inc. · regulatory capital requirement11.6 percent
Citigroup Inc. · private credit exposure22 USD
Citigroup Inc. · expenses14.3 USD
Citigroup Inc. · reserve to funded loans ratio2.6 percent
Citigroup Inc. · cost of credit2.8 USD
Citigroup Inc. · total reserves22 USD
Citigroup Inc. · acl build597 USD
Citigroup Inc. · private credit investment grade percent98 percent
Citigroup Inc. · net income5.8 USD
Citigroup Inc. · efficiency ratio58 percent
Citigroup Inc. · transformation progress90 percent
Citigroup Inc. · deposits1.4 trillion_USD
Citigroup Inc. · eps3.06 USD
Citigroup Inc. · rotce13.1 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Citi targets 10%-11% 2026 RoTCE while keeping efficiency ratio around 60% and U.S. card NCL rate at 4%-4.5% — Source | Via News | pt.VIA.NEWS